Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.
Gabriele ValentiniDörte HuscherAntonella RiccardiSerena FasanoRosaria IraceValentina MessinitiMarco Matucci-CerinicSerena GuiducciOliver DistlerBritta MaurerJérôme AvouacIngo H TarnerMarc FrerixGabriela RiemekastenElise SiegertLászló CzirjákVeronika LórándChristopher P DentonSvetlana NihtyanovaUlrich A WalkerVeronika K JaegerFrancesco Del GaldoGiuseppina AbignanoLidia P AnanievaAna Maria GhergheCarina MihaiJoerg Christoph HenesTim SchmeiserAlessandra VaccaSergey V MoiseevIvan FoeldvariArmando GabrielliBrigitte Krummel-LorenzSimona RednicYannick AllanoreUlf Müeller-LadnerPublished in: Annals of the rheumatic diseases (2019)
The present study might suggest a preventative effect on the occurrence of distinct myocardial manifestations by vasodilator therapy and low-dose ASA.